Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction Guillain−Barré syndrome (GBS) is an immune-mediated peripheral neuropathy, with acute-onset symmetrical flaccid paralysis as its main clinical manifestation (1). GBS encompasses several clinical subtypes, including Miller fisher syndrome, acute inflammatory demyelinating polyradiculoneuropathy, and acute motor axonal neuropathy (AMAN) (2). More than 20% of patients with GBS experience poor outcomes or death, even when managed with timely treatment (3).
1 Introduction The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a significant global impact since its emergence in late 2019.[1] As of September 3, 2022, over 613 million reported infections and over 6.4 million deaths worldwide (https://covid19.who.int).
1. Introduction Addiction is a chronically relapsing brain disease, which is related to the complex interactions between biological factors (pharmacological effects of drugs, genetics, epigenetics, developmental attributes, and neurocircuitry) and environmental factors (social and cultural systems, insufficient social connection, stress, trauma, and exposure to alternative reinforcers) [1,2].
Highlights • Morphine induced cardioprotective effects. • Nalbuphine did not interfer the cardioprotective effect of morhine. • Nalbuphine could be safely selected or combined with morphine for patients with acute myocardial infraction. Abstract Background When combined with morphine, nalbuphine not only does not affect the analgesic effect but also prevents opioid-induced side effects. The authors investigated whether nalbuphine interferes with morphine-induced cardioprotection in rats.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
